Related Experiment Video

Updated: May 12, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics

William G Cance1, Elena Kurenova, Timothy Marlowe

  • 1Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Science Signaling
|March 28, 2013
PubMed

Insights

Focal adhesion kinase (FAK) is a promising cancer target due to its high expression and role in tumor progression. Targeting the FAK scaffold offers a novel therapeutic strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Focal adhesion kinase (FAK) is upregulated in various cancers.
  • FAK plays a critical role in tumor growth, invasion, and metastasis.
  • Current FAK inhibitors target its catalytic activity.

Purpose of the Study:

  • To explore targeting the FAK scaffold as a novel therapeutic strategy.
  • To investigate the potential of disrupting FAK signaling pathways in cancer.

Main Methods:

  • Analysis of FAK expression in cancer.
  • Review of existing FAK-based therapeutics.
  • Evaluation of FAK scaffold targeting strategies.

Main Results:

  • FAK is highly expressed at transcriptional and translational levels in cancer.
  • The FAK scaffold interacts with oncogenic receptor tyrosine kinases and tumor suppressor proteins.
  • Targeting the FAK scaffold presents a feasible approach for developing specific therapeutics.

Conclusions:

  • Targeting the FAK scaffold is a promising strategy for cancer therapy.
  • Disrupting FAK signaling via scaffold inhibition can impede tumor progression.
  • Novel therapeutics can be developed by focusing on the FAK scaffold structure.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...